Lexicon Pharmaceuticals Inc
F:LX31
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lexicon Pharmaceuticals Inc
F:LX31
|
US |
|
M
|
Mobico Group PLC
SWB:3NA
|
UK |
|
A
|
Alba Mineral Resources PLC
OTC:ALBAF
|
UK |
|
M
|
Molson Coors Beverage Co
NYSE:TAP.A
|
US |
|
M
|
Marriott International Inc
XBER:MAQ
|
US |
|
C
|
Christian Dior SE
SWB:DIO
|
FR |
|
K
|
Kikkoman Corp
XMUN:KIK
|
JP |
|
E
|
EDP Renovaveis SA
F:EDW
|
ES |
|
C
|
Capital Ltd
SWB:C8D
|
UK |
|
D
|
Deckers Outdoor Corp
XBER:DO2
|
US |
|
T
|
Teradyne Inc
XMUN:TEY
|
US |
|
B
|
Brera Holdings PLC
NASDAQ:BREA
|
IE |
Wall St Price Targets
LX31 Price Targets Summary
Lexicon Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for LX31 is 4.637 EUR with a low forecast of 2.131 EUR and a high forecast of 7.597 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LX31's stock price target?
Price Target
4.637
EUR
According to Wall Street analysts, the average 1-year price target for LX31 is 4.637 EUR with a low forecast of 2.131 EUR and a high forecast of 7.597 EUR.
What is the Revenue forecast for Lexicon Pharmaceuticals Inc?
Projected CAGR
41%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 41%.
What is the Gross Profit forecast for Lexicon Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Gross Profit over the next 8 years is 41%.
